Austar Lifesciences Limited
AULSF
$0.07
$0.0651,300.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 208.62M | 211.52M | 213.96M | 231.17M | 249.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 208.62M | 211.52M | 213.96M | 231.17M | 249.55M |
| Cost of Revenue | 166.74M | 170.14M | 173.17M | 187.09M | 201.93M |
| Gross Profit | 41.88M | 41.38M | 40.79M | 44.09M | 47.62M |
| SG&A Expenses | 33.21M | 35.20M | 37.12M | 42.02M | 47.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.61M | -2.90M | -2.17M | -1.87M | -1.58M |
| Total Operating Expenses | 203.79M | 209.73M | 215.23M | 234.68M | 255.32M |
| Operating Income | 4.83M | 1.78M | -1.27M | -3.50M | -5.77M |
| Income Before Tax | 2.94M | 171.10K | -2.60M | -3.69M | -4.80M |
| Income Tax Expenses | 1.06M | 766.80K | 477.30K | 270.70K | 64.40K |
| Earnings from Continuing Operations | 1.89 | -0.60 | -3.08 | -3.96 | -4.86 |
| Earnings from Discontinued Operations | -- | -3.34M | -6.68M | -9.00M | -11.38M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 348.30K | 376.40K | 404.00K | 355.50K | 307.60K |
| Net Income | 2.24M | -3.56M | -9.35M | -12.61M | -15.94M |
| EBIT | 4.83M | 1.78M | -1.27M | -3.50M | -5.77M |
| EBITDA | 9.04M | 5.81M | 2.57M | -85.60K | -2.77M |
| EPS Basic | 0.00 | -0.01 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Average Diluted Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |